MYD88 and primary central nervous system lymphoma: Recent studies indicated that a high frequency (>75%) of MYD88 L265P mutations (an adaptor protein mediating toll-like receptor and interleukin-1 signaling) in the DLBCL subtype of PCNSL may be an initiator of disease.